Epidemiology of mumps outbreaks and the impact of an additional dose of MMR vaccine for outbreak control in regional Queensland, Australia, 2017–2018
DOI:
https://doi.org/10.33321/cdi.2021.45.67Keywords:
Mumps, Boarding school, Indigenous, Prison, Outbreak, Queensland, Vaccination, MMR, Additional dose, Infection controlAbstract
Background
In recent years, there have been ongoing outbreaks of mumps reported in Northern and North-Western Queensland, Western Australia and the Northern Territory, Australia. We aimed to define the epidemiology of mumps outbreaks in Central Queensland, Australia between October 2017 and October 2018 and evaluate the effectiveness of an additional dose of measles, mumps, rubella (MMR) vaccine.
Methods
A retrospective case control study was conducted, including outbreak investigations with laboratory-confirmed cases of mumps and subsequent comparison with matched controls. We analysed mandatory notifications from the Queensland Health Notifiable Conditions System database and immunisation information from the Queensland Health Vaccination Information and Admin System (VIVAS) and the Australian Immunisation Register.
Results
Between October 2017 and October 2018, there were 93 cases of mumps reported in Central Queensland with three distinct outbreaks: a discrete Indigenous community; a correctional facility; and a boarding school. Among all cases, 74 (79.6%) were fully vaccinated and 14 (15.1%) were partially vaccinated with MMR vaccine. Eighty-six cases (92.5%) were reported among Aboriginal and Torres Strait Islander people. In all outbreaks, an additional dose of MMR vaccine was offered with 35.4%, 73.6% and 35.8% of the target population being immunised in the discrete Indigenous community, the correctional facility and the boarding school, respectively. Prior to this additional dose of MMR, the mumps attack rate was 31.0 (95% confidence interval [95% CI]: 24.2–39.0) per 1000 population, compared to the post-additional dose MMR attack rate of 10.6 (95% CI: 6.7–15.9) per 1000 population.
Conclusion
An additional or booster dose of MMR should be included as an effective public health intervention strategy, particularly in communal or high-density living conditions to control mumps outbreaks in highly vaccinated populations.
Downloads
References
Ahmed S, Aziz I. Mumps 2017: the role of educational institutes in preventing the spread of the disease. Am J Infect Control . 2017;45(7):817–8.
Australian Government, Australian Institute of Health and Welfare (AIHW). Mumps in Australia . Canberra: Australian Government, AIHW; 2018. Available from: https://www.aihw.gov.au/getmedia/c275433d-4ac8-4968-8207-ee48f07118da/aihw-phe-236_Mumps.pdf.aspx.
Queensland Health. Communicable disease control guidance: Mumps. [Internet.] Brisbane: Queensland Government, Queensland Health; 11 July 2019. Available from: http://disease-control.health.qld.gov.au/Condition/761/mumps.
Westphal DW, Eastwood A, Levy A, Davies J, Huppatz C, Gilles M et al. A protracted mumps outbreak in Western Australia despite high vaccine coverage: a population-based surveillance study. Lancet Infect Dis . 2019;19(2):177–84.
National Centre for Immunisation Research and Surveillance (NCIRS). Significant events in measles, mumps and rubella vacciantion practice in Australia . Sydney: NCIRS; December 2019. Available from: https://www.ncirs.org.au/sites/default/files/2019-12/Measles-mumps-rubella-history-Dec%202019.pdf.
Lewnard JA, Grad YH. Vaccine waning and mumps re-emergence in the United States. Sci Transl Med . 2018;10(433):eaao5945. doi: https://doi.org/10.1126/scitranslmed.aao5945.
Livingston KA, Rosen JB, Zucker JR, Zimmerman CM. Mumps vaccine effectiveness and risk factors for disease in households during an outbreak in New York City. Vaccine . 2014;32(3):369–74.
Vygen S, Fischer A, Meurice L, Mounchetrou Njoya I, Gregoris M, Ndiaye B et al. Waning immunity against mumps in vaccinated young adults, France 2013. Euro Surveill . 2016;21(10):30156. doi: https://doi.org/10.2807/1560-7917.ES.2016.21.10.30156.
Australian Government Department of Health. National Notifiable Diseases Surviellance System. [Website.] Canberra: Australian Government Department of Health; 2020. Available from: http://www9.health.gov.au/cda/source/rpt_2_sel.cfm.
Bailie RS, Wayte KJ. Housing and health in Indigenous communities: key issues for housing and health improvement in remote Aboriginal and Torres Strait Islander communities. Aust J Rural Health . 2006;14(5):178–83.
Huang AS, Cortese MM, Curns AT, Bitsko RH, Jordan HT, Soud F et al. Risk factors for mumps at a university with a large mumps outbreak. Public Health Rep . 2009;124(3):419–26.
Cardemil CV, Dahl RM, James L, Wannemuehler K, Gary HE, Shah M et al. Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control. N Engl J Med . 2017;377(10):947–56.
Australian Institute of Health and Welfare (AIHW). Meteor (Metadata online registry). Discrete Indigenous community - Indigenous community identifier. [Webpage.] Canberra: Australian Government, AIHW; 11 August 2014. Available from: https://meteor.aihw.gov.au/content/index.phtml/itemId/269732.
Australian Government Department of Health. Australian Immunisation Handbook. [Internet.] Canberra: Australian Government Department of Health; 2018. Available from: https://immunisationhandbook.health.gov.au/.
R Core Team. R: a language and environment for statistical computing . Vienna: R Foundation for Statistical Computing; 2020. Available from: https://www.R-project.org/.
Aratchige PE, McIntyre PB, Quinn HE, Gilbert GL. Recent increases in mumps incidence in Australia: the “forgotten” age group in the 1998 Australian Measles Control Campaign. Med J Aust . 2008;189(8):434–7.
Bangor-Jones RD, Dowse GK, Giele CM, van Buynder PG, Hodge MM, Whitty MM. A prolonged mumps outbreak among highly vaccinated Aboriginal people in the Kimberley region of Western Australia. Med J Aust . 2009;191(7):398–401.
Deeks SL, Lim GH, Simpson MA, Gagné L, Gubbay J, Kristjanson E et al. An assessment of mumps vaccine effectiveness by dose during an outbreak in Canada. CMAJ . 2011;183(9):1014–20.
Eriksen J, Davidkin I, Kafatos G, Andrews N, Barbara C, Cohen D et al. Seroepidemiology of mumps in Europe (1996–2008): why do outbreaks occur in highly vaccinated populations? Epidemiol Infect . 2013;141(3):651–66.
Barrabeig I, Antón A, Torner N, Pumarola T, Costa J, Domínguez À et al. Mumps: MMR vaccination and genetic diversity of mumps virus, 2007–2011 in Catalonia, Spain. BMC Infect Dis . 2019;19(1):954.
Zengel J, Phan SI, Pickar A, Xu P, He B. Immunogenicity of mumps virus vaccine candidates matching circulating genotypes in the United States and China. Vaccine . 2017;35(32):3988–94.
Hull BP, McIntyre PB. Timeliness of childhood immunisation in Australia. Vaccine . 2006;24(20):4403–8.
Lovie-Toon YG, Hall KK, Chang AB, Anderson J, O’Grady KAF. Immunisation timeliness in a cohort of urban Aboriginal and Torres Strait Islander children. BMC Public Health . 2016;16(1):1159.
Naidu L, Chiu C, Habig A, Lowbridge C, Jayasinghe S, Wang H, et al. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2006–2010. Commun Dis Intell Q Rep . 2013;37(Suppl):S1–95.
Shah M, Quinlisk P, Weigel A, Riley J, James L, Patterson J et al. Mumps outbreak in a highly vaccinated university-affiliated setting before and after a measles-mumps-rubella vaccination campaign—Iowa, July 2015 – May 2016. Clin Infect Dis . 2018;66(1):81–8.
Guo A, Ayers T, Leung J, Fields V, Va P, Safi H et al. 1723. Mumps Attack Rates Following Administration of a Third Dose of MMR Vaccine to School-Aged Children, Arkansas, 2016–2017. Open Forum Infect Dis . 2018;5(Suppl 1):S54.
Marin M, Marlow M, Moore KL, Patel M. Recommendation of the Advisory Committee on Immunization Practices for use of a third dose of mumps virus–containing vaccine in persons at increased risk for mumps during an outbreak. MMWR Morb Mortal Wkly Rep . 2018;67(1):33–38.
Rubin SA, Qi L, Audet SA, Sullivan B, Carbone KM, Bellini WJ et al. Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak. J Infect Dis . 2008;198(4): 508–15.
Marin M, Fiebelkorn AP, Bi D, Coleman LA, Routh J, Curns AT et al. Adverse events among young adults following a third dose of measles-mumps-rubella vaccine. Clin Infect Dis . 2020. doi: https://doi.org/10.1093/cid/ciaa1090.
Abedi GR, Mutuc JD, Lawler J, Leroy ZC, Hudson JM, Blog DS et al. Adverse events following a third dose of measles, mumps, and rubella vaccine in a mumps outbreak. Vaccine . 2012;30(49):7052–8.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2021 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
